Eloxx Pharmaceuticals Inc (ELOX)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$

Buy

$

arrow-up$ (+%)

Prices updated at 04 Apr 2026, 15:49

Prices minimum 15 mins delay

Prices in USD

Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.

-%

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Tomer Kariv

CEO

Mr. Sumit Aggarwal

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

7

Head office

10 Court Street

Arlington

United States

02476

+1 781 577-5300

barbarar@eloxxpharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Steven D. Rubin Independent Director	0.06m
Mr. Tomer Kariv Chairman of the Board	0.05m
Mr. Daniel E. Geffken, M.B.A. Interim Chief Financial Officer and Principal Accounting Officer	-
Mr. Sumit Aggarwal Director, President and Chief Executive Officer	0.58m
Dr. Alan Walts Independent Director	0.06m
Ms. Lindsay Androski Independent Director	0.03m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Northern Trust Investments Inc	101
NT Quality SCC US Fund - L	101
MissionSquare Retirement	-
T. Rowe Price Associates, Inc.	-
Principal Global Investors LLC	-

Director dealings

Date chevron-l-regular chevron-r-regular	Action
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-
24 Jan 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.